8-K: Neurocrine Biosciences Reports Strong Q1 2024 Results Driven by INGREZZA Sales Growth

Neurocrine Biosciences announced a successful first quarter of 2024, highlighted by a 23% year-over-year increase in INGREZZA sales and positive clinical trial results.

Summary

• Neurocrine Biosciences reported its financial results for the first quarter of 2024, showing significant growth.
• Net product sales for INGREZZA reached $506 million, a 23% increase compared to the same quarter last year.
• Total revenue for the quarter was $515.3 million, up from $420.4 million in Q1 2023.
• The company's GAAP net income was $43.4 million, a significant improvement from a net loss of $76.6 million in the first quarter of 2023.
• Non-GAAP net income was $124.8 million, compared to a non-GAAP net loss of $49.5 million in the prior year's first quarter.
• The company's cash, cash equivalents, and marketable securities totaled approximately $1.9 billion as of March 31, 2024.
• Neurocrine reaffirmed its 2024 INGREZZA net product sales guidance of $2.1 to $2.2 billion.
• The company also updated its expense guidance for 2024, including GAAP R&D expenses between $665 and $695 million and GAAP SG&A expenses between $920 and $940 million.

Sentiment

Score: 9

Explanation: The document conveys a very positive sentiment due to strong financial results, significant clinical progress, and a reaffirmed positive outlook. The company's transition to profitability and the success of INGREZZA are particularly encouraging.

Positives

• INGREZZA sales showed strong growth, indicating continued market demand.
• The company achieved a significant improvement in profitability, moving from a net loss to a net income.
• The company has a strong cash position, providing financial flexibility.
• The company has a robust pipeline with multiple compounds in midto late-phase clinical development.
• The company has made progress with regulatory submissions and approvals.
• Positive clinical trial results for NBI-1065845 suggest potential for a new treatment in major depressive disorder.

Negatives

• The company incurred an $89 million charge related to the settlement of convertible senior notes.
• GAAP R&D expenses increased to $159.4 million from $139.5 million in the same quarter last year.
• GAAP SG&A expenses remained relatively flat at $243.1 million compared to $242.7 million in the prior year.

Risks

• The company's future financial performance is subject to risks and uncertainties.
• The commercial success of INGREZZA is not guaranteed.
• The development of product candidates may face regulatory hurdles or clinical trial failures.
• The company is dependent on third parties for development, manufacturing, and commercialization activities.
• Competition from other therapies or products could impact the company's market share.
• Government and third-party regulatory and/or policy efforts may impose sales and pharmaceutical pricing controls.

Future Outlook

Neurocrine reaffirmed its 2024 INGREZZA net product sales guidance of $2.1 to $2.2 billion and updated its expense guidance for the year. The company also outlined expected pipeline milestones and key activities for the remainder of 2024.

Management Comments

• Kevin Gorman, Ph.D., Chief Executive Officer of Neurocrine Biosciences, stated that significant unmet need still exists for patients with tardive dyskinesia, as evidenced by INGREZZA's growth.
• He also noted that with recent New Drug Application submissions for crinecerfont, positive Phase 2 results for NBI-845, and the deepest pipeline in the company's history, Neurocrine Biosciences is well positioned to become a leader in neuroscience.

Industry Context

This announcement reflects a positive trend in the biopharmaceutical industry, where companies with successful commercial products and promising pipelines are seeing strong growth. Neurocrine's focus on neuroscience and its advancements in treatments for neurological, neuroendocrine, and neuropsychiatric disorders align with the increasing demand for innovative therapies in these areas.

Comparison to Industry Standards

• Neurocrine's 23% year-over-year growth in INGREZZA sales is strong compared to the average growth rates of other pharmaceutical companies in the neurology space, which often see single-digit growth.
• The company's transition to profitability, with a GAAP net income of $43.4 million, is a positive sign, especially when compared to other biotech companies that are still in the development phase and often report losses.
• The submission of New Drug Applications for crinecerfont and positive Phase 2 data for NBI-1065845 are significant milestones, comparable to other companies advancing novel therapies in their respective fields.
• Companies like Teva Pharmaceuticals and AbbVie, which also have products in the neurology space, serve as benchmarks for Neurocrine's commercial performance and pipeline development.

Stakeholder Impact

• Shareholders will likely react positively to the strong financial results and clinical progress.
• Employees may be motivated by the company's success and future prospects.
• Patients may benefit from the development of new treatments for neurological, neuroendocrine, and neuropsychiatric disorders.
• Suppliers and partners may see increased business opportunities due to the company's growth.

Next Steps

• The company will continue to engage with the FDA on the path forward for NBI-1065845.
• Neurocrine will focus on commercializing INGREZZA SPRINKLE.
• The company will advance its pipeline programs, including NBI-1117568 and Luvadaxistat, with top-line Phase 2 data expected in Q3 2024.
• Neurocrine will continue to initiate Phase 1 and Phase 2 studies for other compounds in its pipeline.

Key Dates

Keywords

Neurocrine Biosciences, INGREZZA, valbenazine, tardive dyskinesia, congenital adrenal hyperplasia, NBI-1065845, major depressive disorder, FDA, clinical trials, pharmaceuticals, biotechnology, neuroscience